Abstract
Background
To characterize how prior incisional glaucoma surgery affects the intraocular pressure (IOP) elevation immediately following intravitreal anti-VEGF injections (IVI).
Methods
Single institution, experimental study. Patients with a history of incisional glaucoma surgery who were receiving anti-VEGF injections were recruited as well as control eyes. Pre- and post-injection IOP measurements were compared as well as time to recovery to within 5 and 10 mmHg of baseline IOP.
Results
Ten eyes with a history of glaucoma surgery and 29 control eyes receiving anti-VEGF injections were included. The most common indication for intravitreal anti-VEGF injection was proliferative diabetic retinopathy in both surgical and control eyes (50% vs 45%, p = 1.00). Post-injection IOP was significantly decreased compared to baseline IOP after anti-VEGF injection in surgical versus control eyes (26.5 ± 8.9 mmHg vs 44.2 ± 8.5 mmHg, respectively, p < 0.001). The mean change in IOP following intravitreal anti-VEGF injection was lower in surgical eyes (10.7 ± 6.6 mmHg vs 28.6 ± 8.3 mmHg, p < 0.001). The mean time for the IOP to return to within 10 mmHg of pre-injection IOP was less in surgical eyes (5.2 ± 4.1 min vs 13.3 ± 7.6 min, p = 0.002).
Conclusions
Eyes with prior incisional glaucoma surgery demonstrated a significantly lower post-injection IOP elevation and a faster recovery to within 10 mmHg of their pre-injection IOP. Incisional glaucoma surgery may be considered for patients where the attenuation of post-injection IOP elevation is needed and other less invasive measures have failed.
Similar content being viewed by others
References
Lee JW, Park H, Choi JH et al (2016) Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol 16:69
Kim JE, Mantravadi AV, Hur EY, Covert DJ (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146(6):930–934.e1
Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P (2009) Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 18(9):658–661
Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J (2007) Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 42(6):807–811
Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB (2018) The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol 63(3):281–295
Falkenstein IA, Cheng L, Freeman WR (2007) Changes of intraocular pressure after intravitreal injection of bevacizumab (AVASTIN). Retina. 27(8):1044–1047
Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 23(1):181–185
Zhi Z, Cepurna WO, Johnson EC, Morrison JC, Wang RK (2012) Impact of intraocular pressure on changes of blood flow in the retina, choroid, and optic nerve head in rats investigated by optical microangiography. Biomed Opt Express 3(9):2220–2233
Iwase T, Akahori T, Yamamoto K, Ra E, Terasaki H (2018) Evaluation of optic nerve head blood flow in response to increase of intraocular pressure. Sci Rep 8(1):17235
Shirakashi M (2009) The effects of intraocular pressure elevation on optic nerve axonal transport in the monkey. Acta Ophthalmol 68(1):37–43
Liu X, Li M, Zhong Y, Xiao H, Huang J, Mao Z (2011) The damage patterns of retinal nerve fiber layer in acute and chronic intraocular pressure elevation in primary angle closure glaucoma. Eye Sci 26(3):154–160
Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F et al (2012) Retinal nerve Fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal Ranibizumab. Invest Opthalmol Vis Sci 53(10):6214
Soheilian M, Karimi S, Montahae T, Nikkhah H, Mosavi SA (2017) Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefes Arch Clin Exp Ophthalmol 255(9):1705–1712
Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM (2010) Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monatsbl Augenheilkd 227(4):280–284
Ozcaliskan S, Ozturk F, Yilmazbas P, Beyazyildiz O (2015) Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection. Int J Ophthalmol 8(3):496–500
Sisk RA, Rusia D, Zamora BG, Kuley A, Toussaint BW (2018) Effect of serial anterior chamber paracentesis on sustained intraocular pressure elevation in patients receiving intravitreal anti-vascular endothelial growth factor therapy. Retina. https://doi.org/10.1097/IAE.0000000000002314
Frenkel MPC, Haji SA, Frenkel REP (2010) Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 128(12):1523–1527
Katayama BYNY, Bianka YN, Bonini-Filho MA et al (2014) Comparison of acetazolamide, Brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection. J Glaucoma 23(7):461–463
Murray CD, Wood D, Allgar V, Walters G, Gale RP (2014) Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye. 28(10):1218–1222
Ichiyama Y, Sawada T, Kakinoki M et al (2014) Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration. Ophthalmic Res 52(4):234–238
Carnota-Méndez P, Méndez-Vázquez C, Otero-Villar J, Saavedra-Pazos JA (2014) Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Eur J Ophthalmol 24(5):771–777
Eadie BD, Etminan M, Carleton BC, Maberley DA, Mikelberg FS (2017) Association of Repeated Intravitreous Bevacizumab Injections with Risk for Glaucoma surgery. JAMA Ophthalmol 135(4):363–368
Kim G-N, Han Y-S, Chung I-Y, Seo S-W, Park J-M, Yoo J-M (2013) Effect of Dorzolamide/Timolol or Brinzolamide/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension. Semin Ophthalmol 28(2):61–67
Knip MM, Välimäki J (2012) Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 90(3):254–258
Alaghband P, Beltran-Agulló L, Galvis EA, Overby DR, Lim KS (2018) Effect of phacoemulsification on facility of outflow. Br J Ophthalmol 102(11):1520–1526
Acknowledgments
This work was supported by the National Institutes of Health Core Grant EY001830 and by an unrestricted departmental grant from Research to Prevent Blindness.
Funding
No funding was received for this research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Washington and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lam, J., Luttrell, I., Ding, L. et al. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection. Graefes Arch Clin Exp Ophthalmol 257, 2489–2494 (2019). https://doi.org/10.1007/s00417-019-04431-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-019-04431-x